Journal of Cancer Research and Therapeutics Close
 

Figure 2: Pure ductal carcinoma in situ(a) estrogen receptor immunostaining shows uniformly positive tumor cells (estrogen receptor immunostain), (b) progesterone receptor immunostaining show uniformly positive tumor cells (progesterone receptor immunostain), (c) HER2 immunostain 3+, complete membranous staining (HER2 immunostain), (d) CK8/18 strong cytoplasmic and membranous positivity in tumor epithelial cells in ductal carcinoma in situ(CK8/18 immunostain), (e) CK5/6 immunostain shows strong cytoplasmic and membranous positivity in >10% of tumor epithelial cells in pure ductal carcinoma in situ, basal type (CK5/6 immunostain), and (f) negative CK14 in ductal carcinoma in situ(CK14 immunostain)

Figure 2: Pure ductal carcinoma <i>in situ</i>(a) estrogen receptor immunostaining shows uniformly positive tumor cells (estrogen receptor immunostain), (b) progesterone receptor immunostaining show uniformly positive tumor cells (progesterone receptor immunostain), (c) HER2 immunostain 3+, complete membranous staining (HER2 immunostain), (d) CK8/18 strong cytoplasmic and membranous positivity in tumor epithelial cells in ductal carcinoma <i>in situ</i>(CK8/18 immunostain), (e) CK5/6 immunostain shows strong cytoplasmic and membranous positivity in >10% of tumor epithelial cells in pure ductal carcinoma <i>in situ</i>, basal type (CK5/6 immunostain), and (f) negative CK14 in ductal carcinoma <i>in situ</i>(CK14 immunostain)